Ascletis Joins Hong Kong Stock Connect Programs
Hong Kong, September 7, 2026 Ascletis Pharma Inc. has announced that its ordinary shares have been included as eligible...
Metabolic Diseases
Advertisement
Insilico Medicine Launches AI-Powered Virtual Aging Cell
Hong Kong, August 14, 2026 Insilico Medicine, a clinical-stage drug discovery company powered by generative artificial intelligence (AI), has...
Insilico and THPharm Expand AI Drug Development Strategy
Seoul, South Korea, August 12, 2026 THPharm is advancing an artificial intelligence-driven indication expansion strategy in partnership with Insilico...
Ascletis Begins U.S. Phase I Trials of Monthly Obesity Drugs
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Advertisements
Ascletis Advances ASC30 Phase II Trial in Diabetes
Hong Kong | April 27, 2026 Ascletis Pharma Inc. has announced the successful completion of enrollment in its U.S....
Wave Life Sciences’ RNA Breakthrough Targets Obesity and Liver Disorders
BOSTON, October 29, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology leader in RNA medicines, has...
Advertisement
